Varegacestat PDUFA target action date of April 28, 2027; Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA)
Initial IM-1021 results show objective responses across all dose
Immunome, Inc. (the "Company") (NASDAQ:IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class cancer therapies, announced today that on November 2, 2026, the
Initial results demonstrate objective responses across all dose levels evaluated in heavily pretreated patients with B-cell non-Hodgkin lymphoma (B-NHL)
Objective response rate of 53% observed in response-evaluable
Immunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that its management will present at the
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements across the primary and all key secondary endpoints
If approved,
Rapid oral presentation highlights improvements in patient-reported symptom burden and physical function through week 48
Four presentations build on the previously reported Phase 3 RINGSIDE results
Immunome,
Immunome, Inc. (the "Company") (NASDAQ:IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 1, 2026,
IM-1340 incorporates Immunome's proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed across solid tumors, including neuroendocrine tumors, lung cancer, and colorectal
Immunome, Inc. (the "Company") (NASDAQ:IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on September 1, 2026,
Immunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C.
Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors
Detailed Phase 3 RINGSIDE data presented in an oral session
Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on August 3, 2026, the Compensation
IM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells.The Phase 1 trial is designed to evaluate the safety,
PDUFA target action date set for April 28, 2027
Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company
Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2026, the Compensation
